Chernett Jorey purchased $95K of DFPH

Chernett Jorey purchased 18,000 shares of Oncology Institute, Inc. (DFPH) at $5.27 on 2026-07-21.

Original reporting
SEC EDGAR · Chernett Jorey
Published Jul 22, 2026, 1:55 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 22, 2026, 2:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$DFPH
Neutral
low confidence
Mentioned
$DFPH
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DFPHNeutralLow
01

Why it matters

The newest fact is the reported open-market purchase by a 10% owner at a specific price and share count; it may slightly influence sentiment but does not introduce new operational or financial information.

02

Market read

A disclosed insider buy can be monitored, but this filing alone is unlikely to drive a material repricing without accompanying company catalysts.

03

What to watch

The filing does not state intent, timing constraints, or whether the buyer has other positions; traders should avoid extrapolating to fundamentals from one purchase.

Relevance 4/10Novelty 3/10Timing: New Form 4 filed 2026-07-22, covering a 2026-07-21 purchase.

Background

The article is an SEC Form 4 insider transaction disclosure for Oncology Institute, Inc. (DFPH).

Company-level read

Ticker impact

$DFPHNeutralLow confidence
Context

On 2026-07-21, 10% owner Chernett Jorey bought 18,000 shares of DFPH at $5.2700 for about $94,860, per Form 4.

Expected impact

Likely limited near-term price impact; any effect would be sentiment-driven and small.

Evidence & confidence

Form 4 insider buys can be informative, but the article provides no new company-specific catalyst (no guidance, trial, deal, or regulatory action) and the transaction size is modest relative to typical market moves.

Market effects

No sector-level implications; this is a single-company insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Insider buys under Form 4 can be routine or planned; without a 10b5-1 plan and without follow-on context, the signal may be weak.

Key entities

  • Oncology Institute, Inc.

    Company subject of the Form 4 insider transaction disclosure.

  • Chernett Jorey

    10% owner who purchased 18,000 shares of DFPH at $5.2700 on 2026-07-21.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LYELMedAI 8/10

ARCH Venture Fund XIII, L.P. (CRANDELL KEITH, GILLIS STEVEN) purchased $25.0M of LYEL (indirect holdings)

ARCH Venture Fund XIII, L.P. purchased 2,321,262 indirectly-held shares of Lyell Immunopharma, Inc. (LYEL) at $10.77 ($25.00M total) on 2026-11-04. Filed jointly with ARCH Venture Partners XIII, L.P. (10% owner), ARCH Venture Partners XIII, LLC (10% owner), CRANDELL KEITH (10% owner), GILLIS STEVEN (10% owner), NELSEN ROBERT (10% owner), Burow Kristina (10% owner), BERNS PAUL L (10% owner) and BYBEE CLINTON (10% owner).

$COURMedAI 8/10

Pale Fire Capital SE (Senkypl Dusan, Barta Jan) purchased $31.5M of COUR (indirect holdings)

Pale Fire Capital SE purchased 8,355,251 indirectly-held shares of Coursera, Inc. (COUR) at an average of $3.76 ($3.72–$3.85, $31.45M total) across 3 trades over 2026-11-03 to 2026-11-05. Filed jointly with Pale Fire Capital SICAV a.s. (10% owner), Pale Fire Capital investicni spolecnost a.s. (10% owner), Senkypl Dusan (10% owner) and Barta Jan (10% owner).